Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Shares have a consensus analyst rating of "Buy" from 10 analysts (1 sell, 7 buy, 2 strong buy) with an average 12‑month price target of $8.83; several firms recently raised targets (JMP to $12, Piper Sandler to $8) and Zacks upgraded to strong‑buy.
• AQST trades around $3.24 (52‑week range $2.12–$7.55) with a market cap of about $395M and a negative PE of -4.56; the company reported quarterly EPS of ($0.14)

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received a consensus recommendation of "Buy" from the ten analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.8333.

A number of analysts have commented on AQST shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Wednesday. Piper Sandler upped their target price on shares of Aquestive Therapeutics from $5.00 to $8.00 and gave the company an "overweight" rating in a report on Friday, November 7th. JMP Securities lifted their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a "market outperform" rating in a report on Thursday, October 9th. Zacks Research raised Aquestive Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 17th. Finally, Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in Aquestive Therapeutics by 12.2% during the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company's stock worth $374,000 after acquiring an additional 14,025 shares during the period. First National Bank & Trust Co. of Newtown bought a new position in shares of Aquestive Therapeutics during the second quarter worth approximately $50,000. USAdvisors Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $33,000. Penbrook Management LLC boosted its stake in shares of Aquestive Therapeutics by 93.0% in the second quarter. Penbrook Management LLC now owns 43,585 shares of the company's stock valued at $144,000 after buying an additional 21,000 shares during the period. Finally, Daymark Wealth Partners LLC bought a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $58,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Stock Performance

AQST opened at $3.24 on Friday. The business's 50-day simple moving average is $5.51 and its 200 day simple moving average is $5.24. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $7.55. The firm has a market capitalization of $395.28 million, a PE ratio of -4.56 and a beta of 1.66.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $12.81 million during the quarter, compared to analysts' expectations of $12.94 million. On average, research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.